Hemoglobin News and Research

RSS

New nanosponge safely removes dangerous toxins from bloodstream

Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream - including toxins produced by MRSA, E. coli, poisonous snakes and bees.

15 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Researchers at the University of Montreal have found that the glycated hemoglobin levels of children with type 1 diabetes followed at its affiliated Sainte-Justine Mother and Child University Hospital (CHU Sainte-Justine) is correlated linearly and negatively with household income.

4 Apr 2013

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

30 Mar 2013

Score can predict risk for hospital readmission

A risk score for hospitalized patients can pinpoint those most at risk of having to be readmitted to the hospital for avoidable reasons.

27 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

New model helps identify patients who are at high risk for hospital readmission

Hospital readmissions are a costly problem for patients and for the United States health care system with studies showing nearly 20 percent of Medicare patients are readmitted to the hospital within 30 days of discharge at an annual cost of $17 billion.

26 Mar 2013

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

26 Mar 2013

WUSTL's Wang receives NSF grant to study oxygen consumption rates of individual cells

When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.

21 Mar 2013

Study investigates prognostic indicators for BCa patients treated with RC

A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.

19 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Transfusion of older blood adversely affects patients undergoing cardiac surgery or critical care

Transfusion of donated blood more than three weeks old results in impaired blood vessel function, a new study of hospital patients shows.

11 Mar 2013

Genetic mutation that alters PIEZO1 ion channel in RBCs contributes to familial xerocytosis

A genetic mutation that alters the kinetics of an ion channel in red blood cells has been identified as the cause behind a hereditary anemia, according to a paper published this month in the Proceedings of the National Academy of Sciences by University at Buffalo scientists and colleagues.

11 Mar 2013

Aarbepoetin alfa does not improve anemic heart failure patients' health

Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients -darbepoetin alfa - does not improve patients' health, nor does it reduce their risk of death from heart failure.

11 Mar 2013

IV iron dextran alternative to oral iron for anemia in nondialysis CKD

Treatment with intravenous low-molecular-weight iron dextran seems to be an effective alternative for patients with nondialysis chronic kidney disease who remain anemic despite receiving oral iron and erythropoiesis-stimulating agents.

8 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

FDA accepts AMAG’s Feraheme sNDA for review

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012.

6 Mar 2013